Completed PHASE2 INTERVENTIONAL 3-arm NCT00198393

Randomized Phase 2 Study of 3 Therapeutic Modalities in PS 2/3 Patients With NSCLC Stage IIIB/IV

Sponsor: AstraZeneca

Conditions Carcinoma, Non-Small-Cell Lung

Interventions Docetaxel Gefitinib gemcitabine

Updated 5 times since 2017 Last updated: Apr 28, 2010 Started: Nov 30, 2004 Primary completion: Jun 30, 2008 Completion: Dec 31, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Carcinoma, Non-Small-Cell Lung and is currently completed. AstraZeneca leads this study, which shows 5 recorded versions since 2004 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Nov 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

AstraZeneca
Intergroupe Francophone de Cancerologie Thoracique
Sanofi

Data source: Intergroupe Francophone de Cancerologie Thoracique

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Bobigny, France
• Grenoble, France